---
schema_version: "secwatch.filing_event.v1"
accession: "0001750284-25-000007"
form_type: "8-K"
ticker: "OLMA"
cik: "0001750284"
company_name: "Olema Pharmaceuticals, Inc."
filed_at: "2025-09-02T23:59:59+00:00"
generated_at: "2026-05-17T08:55:25.511027+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Olema enters clinical trial agreement with Pfizer for palazestrant + atirmociclib phase 1b/2

## Summary
- Phase 1b/2 study to evaluate safety and combinability of palazestrant plus Pfizer’s investigational CDK4 inhibitor atirmociclib in ER+/HER2- metastatic breast cancer.
- Study planned for approximately 35 patients with initiation anticipated in H2 2025.
- Results to inform potential Phase 3 pivotal trial in frontline metastatic setting.
- Olema retains full global commercial and marketing rights to palazestrant; Pfizer supplies atirmociclib.
- This is Olema’s second clinical trial agreement with Pfizer; prior agreement from Nov 2020 for palazestrant + palbociclib.

## SEC filing metadata
- accession: 0001750284-25-000007
- form_type: 8-K
- ticker: OLMA
- cik: 0001750284
- company_name: Olema Pharmaceuticals, Inc.
- filed_at: 2025-09-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750284/000175028425000007/0001750284-25-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750284/000175028425000007/olma-20250902.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001750284-25-000007
- JSON: https://secwatch.observer/filing/0001750284-25-000007.json
- Plain text: https://secwatch.observer/filing/0001750284-25-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.